Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area | Chiu et al. Journal of Translational Medicine 2011 9 31 http content 9 1 31 TRANSLATIONAL MEDICINE RESEARCH Open Access High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area 4 6t 2 4 51 2 4 1 4 2 4 3 131-jan Chiu Chang-Han Chen Chih-Yen Chien Shau-Hsuan LI nsin-iing isai and Yi-Ju Chen Abstract Background This study was to evaluate the effect of excision repair cross-complementation group 1 ERCC1 expression on response to cisplatin-based induction chemotherapy IC followed by concurrent chemoradiation CCRT in locally advanced unresectable head and neck squamous cell carcinoma HNSCC patients. Methods Fifty-seven patients with locally advanced unresectable HNSCC who received cisplatin-based IC followed by CCRT from January 1 2006 through January 1 2008. Eligibility criteria included presence of biopsy-proven HNSCC without a prior history of chemotherapy or radiotherapy. Immunohistochemistry was used to assess ERCC1 expression in pretreatment biopsy specimens from paraffin blocks. Clinical parameters including smoking alcohol consumption and betel nuts chewing were obtained from the medical records. Results The 12-month progression-free survival PFS and 2-year overall survival OS rates of fifty-seven patients were and respectively. Among these patients thirty-one patients had low ERCC1 expression and forty-one patients responded to IC followed by CCRT. Univariate analyses showed that patients with low expression of ERCC1 had a significantly higher 12-month PFS rates vs. p and 2-year OS vs. p rates. Multivariate analysis showed that for patients who did not chew betel nuts and had low expression of ERCC1 were independent predictors for prolonged survival. Conclusions Our study suggest that a high expression of ERCC1 predict a poor response and survival to cisplatinbased IC followed by
